SELLAS Life Sciences Group, Inc.
Report updated data from GPS combination studies in ovarian and malignant pleural mesothelioma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we look forward to providing further data from these studies in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company reported updated clinical data for both the GPS-nivolumab (MPM) and GPS-pembrolizumab (ovarian cancer) combination studies in June 2021, meeting the first-half 2021 deadline.
-
A SELLAS Life Sciences Group, Inc. 8-K filed 2021-08-12
“We were pleased to report in June updated clinical data for our two earlier stage studies of GPS in combination with PD-1 inhibitors – the combination of GPS with nivolumab (Opdivo®) in MPM patients and GPS with pembrolizumab (Keytruda®) in advanced ovarian cancer patients.” ✓ confirmed on the page
Market reaction: the shares moved +1.9% against the S&P 500 over the three sessions around the disclosure (11 Aug 2021 to 16 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- updated clinical trial data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-SLS-022052 · Corrections policy